var data={"title":"Treatment and prevention of schistosomiasis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment and prevention of schistosomiasis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/contributors\" class=\"contributor contributor_credentials\">Patrick Soentjens, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/contributors\" class=\"contributor contributor_credentials\">Joannes Clerinx, MD, DTM</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/contributors\" class=\"contributor contributor_credentials\">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 01, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H13464824\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Schistosomiasis is a disease caused by infection with parasitic blood flukes. The three major species are <em>Schistosoma mansoni </em>(Africa and South America), <em>S. japonicum</em> (East Asia), and <em>S. haematobium</em> (Africa and the Middle East). The two minor species are <em>S. mekongi</em> (Laos, Cambodia) and <em>S. intercalatum</em> (West and Central Africa).</p><p>The treatment and prevention of schistosomiasis will be reviewed here. The epidemiology, pathogenesis, clinical features, and diagnosis of schistosomiasis are discussed separately. (See <a href=\"topic.htm?path=epidemiology-pathogenesis-and-clinical-manifestations-of-schistosomiasis\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, and clinical manifestations of schistosomiasis&quot;</a> and <a href=\"topic.htm?path=diagnosis-of-schistosomiasis\" class=\"medical medical_review\">&quot;Diagnosis of schistosomiasis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H13464830\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of schistosomiasis serves three purposes: reversing acute or early chronic disease, preventing complications associated with chronic infection, and preventing neuroschistosomiasis. The goal of treatment is reduction of egg production via reduction of worm load; this reduces morbidity and mortality even in the absence of complete worm eradication [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Benefits of treatment include reversal of hydronephrosis and regression of periportal fibrosis and portal hypertension. Treatment is not beneficial for reversing late-stage fibrosis of the hepatic or urinary tract or reversing secondary complications such as esophageal varices or cor pulmonale.</p><p class=\"headingAnchor\" id=\"H7370613\"><span class=\"h2\">Clinical approach</span></p><p class=\"headingAnchor\" id=\"H5762846\"><span class=\"h3\">Acute infection</span></p><p class=\"headingAnchor\" id=\"H5763226\"><span class=\"h4\">Swimmer's itch</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Swimmer's itch is usually caused by nonhuman schistosome species; humans are not suitable hosts so the organism dies while in the skin. The rash typically clears within a few days; treatment consists of symptomatic management for pruritus. (See <a href=\"topic.htm?path=pruritus-overview-of-management\" class=\"medical medical_review\">&quot;Pruritus: Overview of management&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H5762942\"><span class=\"h4\">Acute schistosomiasis syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acute schistosomiasis syndrome (known as Katayama fever) is a systemic hypersensitivity reaction to schistosome antigens and circulating immune complexes that occurs three to eight weeks after infection; clinical manifestations are discussed further separately. (See <a href=\"topic.htm?path=epidemiology-pathogenesis-and-clinical-manifestations-of-schistosomiasis#H6283799\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, and clinical manifestations of schistosomiasis&quot;, section on 'Acute schistosomiasis syndrome'</a>.)</p><p>Initial management of acute schistosomiasis syndrome consists of reduction of inflammation with corticosteroids [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/2,3\" class=\"abstract_t\">2,3</a>]. The optimum dose and duration of corticosteroids are uncertain; treatment with <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> 20 to 40 mg daily for five days is generally sufficient to suppress symptoms [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/4,5\" class=\"abstract_t\">4,5</a>].</p><p>Subsequently, <a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">praziquantel</a> should be administered; the optimal timing is uncertain since treatment with praziquantel may aggravate symptoms of acute schistosomiasis. In general, administration of praziquantel is most effective at least four to six weeks following exposure when infection is well established and the worms have fully matured [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/6\" class=\"abstract_t\">6</a>]. Data on optimal timing of treatment are limited; most favor administration of praziquantel after acute symptoms have subsided followed by repeat treatment four to six weeks thereafter.</p><p><a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">Praziquantel</a> should be initiated only after acute symptoms have resolved and should be administered concomitantly with corticosteroids [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/2,7,8\" class=\"abstract_t\">2,7,8</a>]. Corticosteroids reduce plasma levels of praziquantel, although data are limited regarding whether the dosing of praziquantel warrants adjustment in the setting of corticosteroids [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/9\" class=\"abstract_t\">9</a>].</p><p class=\"headingAnchor\" id=\"H5762853\"><span class=\"h3\">Chronic infection</span></p><p class=\"headingAnchor\" id=\"H2484781\"><span class=\"h4\">Overview</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with schistosomiasis should be treated with <a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">praziquantel</a>. Since praziquantel is not effective against the larval stages of schistosomes, treatment is most effective from four to six weeks after exposure onwards, when infection is well established and worms have fully matured [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/6,10-12\" class=\"abstract_t\">6,10-12</a>]. In one animal model, praziquantel had no activity in the first 21 days after infection, low activity at day 28, and 100 percent activity at day 52 [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/13\" class=\"abstract_t\">13</a>].</p><p>In general, patients with known recent exposure should have treatment deferred until diagnostic serology <span class=\"nowrap\">and/or</span> microscopy can be performed (generally positive 6 to 12 weeks after exposure). Patients with relevant exposure and compatible clinical symptoms may be treated initially with corticosteroids, followed by subsequent administration of <a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">praziquantel</a> once the diagnosis has been confirmed and the worms have matured sufficiently for treatment to be successful. (See <a href=\"#H5762942\" class=\"local\">'Acute schistosomiasis syndrome'</a> above.)</p><p>Administration of <a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">praziquantel</a> to patients with recent infection may induce symptoms of acute schistosomiasis within a few days of therapy. However, prolonged delay prior to administration of praziquantel (up to 12 weeks after infection) may increase risk for development of neuroschistosomiasis.</p><p>In endemic areas, a single dose of <a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">praziquantel</a> is curative in more than 85 percent of cases; among individuals who are not cured, praziquantel reduces the parasite burden by more than 90 percent [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/14-17\" class=\"abstract_t\">14-17</a>]. Retreatment of patients with residual infection further increases cure rates [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/18-20\" class=\"abstract_t\">18-20</a>]. Among travelers and expatriates with low parasite burden, a single dose of praziquantel is generally sufficient for reducing the worm burden to negligible levels [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/21\" class=\"abstract_t\">21</a>].</p><p>Dosing of <a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">praziquantel</a> for infection due to <em>S. haematobium</em>, <em>S. mansoni,</em> or <em>S. intercalatum</em> consists of 40 <span class=\"nowrap\">mg/kg</span> (in one or two divided doses) [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/20\" class=\"abstract_t\">20</a>]. Dosing for infection due to <em>S. japonicum</em> or <em>S. mekongi</em> consists of 60 <span class=\"nowrap\">mg/kg</span> (in two divided doses) [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/14,15,21\" class=\"abstract_t\">14,15,21</a>]. A repeat dose of praziquantel given two weeks after the initial dose may improve cure rate and improve the intensity of <em>S. mansoni</em> infection, although this is not a standard practice [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/19\" class=\"abstract_t\">19</a>].</p><p>Follow-up after treatment includes monitoring of clinical manifestations, eosinophil count (in patients with eosinophilia), and microscopy evaluation for eggs in stool or urine. In populations with a high parasite burden, medical imaging techniques (abdominal ultrasound or magnetic resonance imaging) are essential to document long-term reversal of urinary tract lesions and of periportal liver disease following repeated mass treatment [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/22\" class=\"abstract_t\">22</a>]. Eosinophil levels may increase shortly after treatment and subsequently decrease over several weeks [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/23\" class=\"abstract_t\">23</a>].</p><p>Persistent eosinophilia for more than three months after treatment may reflect insufficient reduction of parasite burden <span class=\"nowrap\">and/or</span> may indicate the presence of an additional helminth infection. Serology is not a useful monitoring tool as it remains positive for prolonged periods following treatment.</p><p>In endemic areas, follow-up microscopy of stool or urine for assessment of cure should be performed no sooner than six weeks following treatment. In nonendemic areas, follow-up microscopy may be performed three to six months after treatment, since there is no risk of intercurrent reinfection [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/24\" class=\"abstract_t\">24</a>]. Egg excretion may continue for a few weeks after treatment, and differentiating viable eggs from nonviable eggs may be difficult. In addition, treatment may cause temporary cessation of egg production from adult worms that are not killed.</p><p>Presence of viable eggs 6 to 12 weeks after initial therapy warrants repeat treatment with <a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">praziquantel</a>. The same dose of praziquantel (40 <span class=\"nowrap\">mg/kg</span> for infection due to <em>S. haematobium</em>, <em>S. mansoni,</em> or <em>S. intercalatum</em>; 60 <span class=\"nowrap\">mg/kg</span> for infection due to <em>S. japonicum</em> or <em>S. mekongi</em>) may be administered [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/21\" class=\"abstract_t\">21</a>]. There does not appear to be an advantage to increasing the dose in retreatment [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/11,25\" class=\"abstract_t\">11,25</a>].</p><p>Issues related to population deworming are discussed separately. (See <a href=\"topic.htm?path=mass-drug-administration-for-control-of-parasitic-infections#H10826524\" class=\"medical medical_review\">&quot;Mass drug administration for control of parasitic infections&quot;, section on 'Clinical approach'</a>.)</p><p class=\"headingAnchor\" id=\"H5763365\"><span class=\"h4\">Genitourinary schistosomiasis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Urinary schistosomiasis can cause genital lesions during childhood in boys and girls. It increases vaginal mucosal fragility and bleeding in women and has been associated with increased HIV acquisition in several studies [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/26\" class=\"abstract_t\">26</a>]. Although genital lesions are chronic, it is assumed that early and repeated treatment with <a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">praziquantel</a> could substantially reduce HIV incidence [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/27\" class=\"abstract_t\">27</a>]. Genital schistosomiasis has been associated with female infertility [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/28\" class=\"abstract_t\">28</a>].</p><p>Issues related to schistosomiasis and glomerular disease are discussed separately. (See <a href=\"topic.htm?path=schistosomiasis-and-glomerular-disease\" class=\"medical medical_review\">&quot;Schistosomiasis and glomerular disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H332980396\"><span class=\"h4\">Hepatosplenic schistosomiasis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hepatosplenic schistosomiasis can cause severe portal hypertension and gastrointestinal bleeding. Splenectomy has been successful for management in some reports [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/29,30\" class=\"abstract_t\">29,30</a>]; further study is needed. In one case series including 45 patients with hepatosplenic schistosomiasis who underwent splenectomy, reduction in portal hypertension and improvement in coagulation factors and liver function tests were observed [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/29\" class=\"abstract_t\">29</a>].</p><p>Patients with hepatosplenic schistosomiasis in the absence of known renal disease warrant annual screening for renal dysfunction via measurement of serum creatinine urine dipstick testing (to evaluate for presence of proteinuria <span class=\"nowrap\">and/or</span> hematuria). If an abnormal urine dipstick result is observed, the urine sediment should be examined and proteinuria should be quantified with a urine protein-to-creatinine ratio. </p><p>Issues related to schistosomiasis and glomerular disease are discussed separately. (See <a href=\"topic.htm?path=schistosomiasis-and-glomerular-disease\" class=\"medical medical_review\">&quot;Schistosomiasis and glomerular disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2484977\"><span class=\"h4\">Neuroschistosomiasis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neuroschistosomiasis develops as a result of embolization of adult worms to the spinal cord or cerebral microcirculation, with subsequent release of eggs leading to an intense inflammatory reaction with local tissue destruction and scarring. It can cause cerebral disease or myelopathy; the latter is more common. Clinical manifestations are discussed further separately. (See <a href=\"topic.htm?path=epidemiology-pathogenesis-and-clinical-manifestations-of-schistosomiasis#H3347989\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, and clinical manifestations of schistosomiasis&quot;, section on 'Neuroschistosomiasis'</a>.)</p><p>Prompt corticosteroid treatment (<a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> 1 to 2 <span class=\"nowrap\">mg/kg)</span> is essential to prevent irreversible tissue damage that occurs as a result of the intense inflammatory response [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/31-33\" class=\"abstract_t\">31-33</a>]. If the diagnosis of neuroschistosomiasis is suspected but not proven, corticosteroid therapy should be administered nonetheless. The approach to diagnosis is discussed separately. (See <a href=\"topic.htm?path=diagnosis-of-schistosomiasis#H30355008\" class=\"medical medical_review\">&quot;Diagnosis of schistosomiasis&quot;, section on 'Neuroschistosomiasis'</a>.)</p><p>The duration of corticosteroid therapy is uncertain; in general, treatment should be continued for two weeks to six months but should be tailored to individual circumstances. In one study including 16 patients with myeloradiculopathy due to neuroschistosomiasis, the best clinical outcome was achieved among patients who received steroid treatment for at least two months [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/34\" class=\"abstract_t\">34</a>]. In the setting of prolonged corticosteroid use, concomitant infection with <em>Strongyloides</em> should to be excluded or treated to prevent the syndrome of strongyloidiasis hyperinfection (see <a href=\"topic.htm?path=strongyloidiasis\" class=\"medical medical_review\">&quot;Strongyloidiasis&quot;</a>).</p><p><a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">Praziquantel</a> (40 <span class=\"nowrap\">mg/kg</span> single dose) can provoke an inflammatory response with paradoxical worsening of neurologic symptoms and should therefore be administered a few days after initiation of corticosteroid treatment [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/35-37\" class=\"abstract_t\">35-37</a>]. Praziquantel may be sufficient for elimination of adult worms and halting egg production, but it does not inactivate eggs embedded at ectopic sites [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/38\" class=\"abstract_t\">38</a>]. In the setting of associated seizures, anticonvulsant therapy should be administered. (See <a href=\"topic.htm?path=overview-of-the-management-of-epilepsy-in-adults#H3\" class=\"medical medical_review\">&quot;Overview of the management of epilepsy in adults&quot;, section on 'Antiseizure drug therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H2484726\"><span class=\"h2\">Anthelminthic therapy</span></p><p class=\"headingAnchor\" id=\"H13464848\"><span class=\"h3\">Praziquantel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">Praziquantel</a> alters the tegument structure of adult worms and increases calcium ion permeability. Calcium ions accumulate in the cytosol, leading to muscular contractions and subsequent paralysis. Damage to the tegument membrane also induces a host immune response to parasite antigens [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/39\" class=\"abstract_t\">39</a>]. Therefore, the efficacy of praziquantel depends on both the parasite burden of infection and the host immune defense [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/40\" class=\"abstract_t\">40</a>].</p><p><a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">Praziquantel</a> is readily absorbed when taken orally with food [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/9\" class=\"abstract_t\">9</a>]. Adverse effects of praziquantel occur in approximately one-third of patients and are generally mild. They include dizziness, headache, vomiting, abdominal pain, diarrhea, and pruritus. These symptoms may be attributable to the drug itself <span class=\"nowrap\">and/or</span> to the host immune response to dying parasites. Therefore, adverse effects may be observed more frequently among patients with high parasite burden [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/41\" class=\"abstract_t\">41</a>]. Paradoxical hypersensitivity reactions following treatment with praziquantel may be observed among travelers with acute infection <span class=\"nowrap\">and/or</span> in the setting of early chronic schistosomiasis [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/7,41,42\" class=\"abstract_t\">7,41,42</a>].</p><p><a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">Praziquantel</a> is pregnancy category B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table graphicRef50021 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/43-47\" class=\"abstract_t\">43-47</a>]. One trial including 370 pregnant women randomized to receive praziquantel or placebo noted no significant differences in safety outcomes including abortion, fetal death in utero, and congenital abnormalities [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/47\" class=\"abstract_t\">47</a>]. Praziquantel is excreted in human breast milk, although no adverse effects during lactation have been reported; most favor discontinuation of breastfeeding at the time of treatment and for 72 hours thereafter or delaying treatment until after breastfeeding.</p><p class=\"headingAnchor\" id=\"H7366350\"><span class=\"h3\">Drug resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Schistosome species with reduced sensitivity to <a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">praziquantel</a> in vivo and in vitro have been described [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/41,48-53\" class=\"abstract_t\">41,48-53</a>]; it is unclear if these observations represent resistance or reinfection. In addition, the distinction between worm burden reduction and failure to eradicate infection in these reports is not always clear.</p><p>In a region of <em>S. mansoni</em> transmission in Senegal, <a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">praziquantel</a> was curative among only 35 percent of individuals; this may be related to high parasite burden and intense transmission with rapid reinfection [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/49,50\" class=\"abstract_t\">49,50</a>]. Another report noted that <em>S. mansoni</em> parasites demonstrated reduced killing upon exposure to praziquantel in vitro [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/53\" class=\"abstract_t\">53</a>]. Therapeutic failure has also been reported in travelers [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/51,52,54,55\" class=\"abstract_t\">51,52,54,55</a>].</p><p class=\"headingAnchor\" id=\"H7366108\"><span class=\"h3\">Alternative therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Oxamniquine has been used for refractory schistosomiasis infection and may be as effective as <a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">praziquantel</a>; it is contraindicated in pregnancy and in general is not as effective as praziquantel [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/56,57\" class=\"abstract_t\">56,57</a>]. Artemisinin derivatives act on the glucose metabolism of immature schistosomes [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/58\" class=\"abstract_t\">58</a>] and could be of use in very early infection [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/6\" class=\"abstract_t\">6</a>]. <a href=\"topic.htm?path=mefloquine-drug-information\" class=\"drug drug_general\">Mefloquine</a> has limited action on mature worms. The addition of mefloquine or <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a> to praziquantel is not beneficial [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/59\" class=\"abstract_t\">59</a>]. Combination praziquantel with artemether may offer some benefit [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/60\" class=\"abstract_t\">60</a>].</p><p class=\"headingAnchor\" id=\"H13464908\"><span class=\"h1\">PREVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Schistosomiasis control strategies for endemic areas include water sanitation programs, mass treatment, and vaccine development. These and other measures have facilitated eradication of schistosomiasis in Japan and have been adopted as a national strategy in China [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/61,62\" class=\"abstract_t\">61,62</a>].</p><p>Minimizing contact with fresh water containing infectious cercarial larvae is an important control measure. Direct contact with fresh water can be reduced by provision of safe water supplies with proper sewage control as well as community education regarding wearing protective clothing and footwear in the setting of freshwater contact [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/63\" class=\"abstract_t\">63</a>]. Other measures may include vigorous toweling of exposed skin <span class=\"nowrap\">and/or</span> applying insect repellent DEET (N,N-diethyl-m-toluamide) after exposure to fresh water [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/64\" class=\"abstract_t\">64</a>]. Eradication of snail species via molluscicides or environmental control of snail breeding sites has been attempted, although it is difficult to sustain because repopulation can occur rapidly [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/63,65\" class=\"abstract_t\">63,65</a>].</p><p>Repeated mass treatment can substantially reduce the prevalence and morbidity of schistosomiasis by keeping the parasite load low and by increasing resistance to reinfection [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/66\" class=\"abstract_t\">66</a>]. (See <a href=\"topic.htm?path=mass-drug-administration-for-control-of-parasitic-infections#H10826524\" class=\"medical medical_review\">&quot;Mass drug administration for control of parasitic infections&quot;, section on 'Clinical approach'</a>.)</p><p>There is no effective vaccine against schistosomiasis [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/67-71\" class=\"abstract_t\">67-71</a>]; further studies are under way [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/72\" class=\"abstract_t\">72</a>].</p><p class=\"headingAnchor\" id=\"H13464920\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment of schistosomiasis serves three purposes: reversing acute or early chronic disease, preventing complications associated with chronic infection, and preventing neuroschistosomiasis. The goal of treatment is reduction of egg production via reduction of worm load. (See <a href=\"#H13464830\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend that patients with schistosomiasis be treated promptly with <a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">praziquantel</a> in the presence or absence of clinical manifestations (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). A single dose of praziquantel reduces the parasite burden substantially though is not curative for moderate or severe infection. (See <a href=\"#H7370613\" class=\"local\">'Clinical approach'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dosing of <a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">praziquantel</a> for treatment of infection due to <em>Schistosoma haematobium</em>, <em>S. mansoni,</em> or <em>S. intercalatum</em> consists of 40 <span class=\"nowrap\">mg/kg</span> (in one or two divided doses). Praziquantel dosing for treatment of infection due to <em>S. japonicum</em> or <em>S. mekongi</em> consists of 60 <span class=\"nowrap\">mg/kg</span> (in two divided doses). (See <a href=\"#H7370613\" class=\"local\">'Clinical approach'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Follow-up after treatment includes monitoring of clinical manifestations, eosinophilia, and microscopy evaluation for eggs in stool or urine. In endemic areas, follow-up microscopy should be performed no sooner than six weeks following treatment. In nonendemic areas, follow-up microscopy may be performed three to six months after treatment. Persistence of viable eggs after treatment with <a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">praziquantel</a> warrants repeat treatment. (See <a href=\"#H7370613\" class=\"local\">'Clinical approach'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Initial management of acute schistosomiasis syndrome consists of reduction of inflammation with corticosteroids. <a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">Praziquantel</a> should be initiated only after acute symptoms have resolved and should be administered concomitantly with corticosteroids. (See <a href=\"#H5762942\" class=\"local\">'Acute schistosomiasis syndrome'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment of neuroschistosomiasis consists of prompt corticosteroid treatment. <a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">Praziquantel</a> should be administered a few days after initiation of corticosteroid treatment; the two therapies should be given concomitantly. (See <a href=\"#H2484977\" class=\"local\">'Neuroschistosomiasis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Schistosomiasis control strategies for endemic areas include water sanitation programs and mass treatment. (See <a href=\"#H13464908\" class=\"local\">'Prevention'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H13464927\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Karin Leder, MD, and Peter Weller, MD, who contributed to an earlier version of this topic.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/1\" class=\"nounderline abstract_t\">Richter J. The impact of chemotherapy on morbidity due to schistosomiasis. Acta Trop 2003; 86:161.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/2\" class=\"nounderline abstract_t\">Jaur&eacute;guiberry S, Paris L, Caumes E. Acute schistosomiasis, a diagnostic and therapeutic challenge. Clin Microbiol Infect 2010; 16:225.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/3\" class=\"nounderline abstract_t\">Ross AG, Vickers D, Olds GR, et al. Katayama syndrome. Lancet Infect Dis 2007; 7:218.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/4\" class=\"nounderline abstract_t\">Chapman PJ, Wilkinson PR, Davidson RN. Acute schistosomiasis (Katayama fever) among British air crew. BMJ 1988; 297:1101.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/5\" class=\"nounderline abstract_t\">Harries AD, Cook GC. Acute schistosomiasis (Katayama fever): clinical deterioration after chemotherapy. J Infect 1987; 14:159.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/6\" class=\"nounderline abstract_t\">Grandi&egrave;re-P&eacute;rez L, Ansart S, Paris L, et al. Efficacy of praziquantel during the incubation and invasive phase of Schistosoma haematobium schistosomiasis in 18 travelers. Am J Trop Med Hyg 2006; 74:814.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/7\" class=\"nounderline abstract_t\">Bottieau E, Clerinx J, de Vega MR, et al. Imported Katayama fever: clinical and biological features at presentation and during treatment. J Infect 2006; 52:339.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/8\" class=\"nounderline abstract_t\">Jaur&eacute;guiberry S, Paris L, Caumes E. Difficulties in the diagnosis and treatment of acute schistosomiasis. Clin Infect Dis 2009; 48:1163.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/9\" class=\"nounderline abstract_t\">Vazquez ML, Jung H, Sotelo J. Plasma levels of praziquantel decrease when dexamethasone is given simultaneously. Neurology 1987; 37:1561.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/10\" class=\"nounderline abstract_t\">Danso-Appiah A, Utzinger J, Liu J, Olliaro P. Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev 2008; :CD000053.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/11\" class=\"nounderline abstract_t\">Danso-Appiah A, Olliaro PL, Donegan S, et al. Drugs for treating Schistosoma mansoni infection. Cochrane Database Syst Rev 2013; :CD000528.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/12\" class=\"nounderline abstract_t\">Ross AG, Bartley PB, Sleigh AC, et al. Schistosomiasis. N Engl J Med 2002; 346:1212.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/13\" class=\"nounderline abstract_t\">Utzinger J, Keiser J, Shuhua X, et al. Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials. Antimicrob Agents Chemother 2003; 47:1487.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/14\" class=\"nounderline abstract_t\">Guisse F, Polman K, Stelma FF, et al. Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal. Am J Trop Med Hyg 1997; 56:511.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/15\" class=\"nounderline abstract_t\">King CH, Wiper DW 3rd, De Stigter KV, et al. Dose-finding study for praziquantel therapy of Schistosoma haematobium in Coast Province, Kenya. Am J Trop Med Hyg 1989; 40:507.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/16\" class=\"nounderline abstract_t\">Berhe N, Gundersen SG, Abebe F, et al. Praziquantel side effects and efficacy related to Schistosoma mansoni egg loads and morbidity in primary school children in north-east Ethiopia. Acta Trop 1999; 72:53.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/17\" class=\"nounderline abstract_t\">Shekhar KC. Schistosomiasis drug therapy and treatment considerations. Drugs 1991; 42:379.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/18\" class=\"nounderline abstract_t\">Ismail MM, Attia MM, el-Badawy AA, et al. Treatment of schistosomiasis with praziquantel among school children. J Egypt Soc Parasitol 1994; 24:487.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/19\" class=\"nounderline abstract_t\">Tukahebwa EM, Vennervald BJ, Nuwaha F, et al. Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda. Trans R Soc Trop Med Hyg 2013; 107:397.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/20\" class=\"nounderline abstract_t\">Kramer CV, Zhang F, Sinclair D, Olliaro PL. Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev 2014; :CD000053.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/21\" class=\"nounderline abstract_t\">Utzinger J, N'Goran EK, N'Dri A, et al. Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Trop Med Int Health 2000; 5:771.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/22\" class=\"nounderline abstract_t\">Olveda DU, Olveda RM, Lam AK, et al. Utility of Diagnostic Imaging in the Diagnosis and Management of Schistosomiasis. Clin Microbiol 2014; 3.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/23\" class=\"nounderline abstract_t\">Ottesen EA, Weller PF. Eosinophilia following treatment of patients with schistosomiasis mansoni and Bancroft's filariasis. J Infect Dis 1979; 139:343.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/24\" class=\"nounderline abstract_t\">Lucey DR, Maguire JH. Schistosomiasis. Infect Dis Clin North Am 1993; 7:635.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/25\" class=\"nounderline abstract_t\">Olliaro PL, Vaillant MT, Belizario VJ, et al. A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Negl Trop Dis 2011; 5:e1165.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/26\" class=\"nounderline abstract_t\">Mbabazi PS, Andan O, Fitzgerald DW, et al. Examining the relationship between urogenital schistosomiasis and HIV infection. PLoS Negl Trop Dis 2011; 5:e1396.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/27\" class=\"nounderline abstract_t\">Ndeffo Mbah ML, Poolman EM, Atkins KE, et al. Potential cost-effectiveness of schistosomiasis treatment for reducing HIV transmission in Africa--the case of Zimbabwean women. PLoS Negl Trop Dis 2013; 7:e2346.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/28\" class=\"nounderline abstract_t\">Kjetland EF, Kurewa EN, Mduluza T, et al. The first community-based report on the effect of genital Schistosoma haematobium infection on female fertility. Fertil Steril 2010; 94:1551.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/29\" class=\"nounderline abstract_t\">Leite LA, Pimenta Filho AA, Ferreira Rde C, et al. Splenectomy Improves Hemostatic and Liver Functions in Hepatosplenic Schistosomiasis Mansoni. PLoS One 2015; 10:e0135370.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/30\" class=\"nounderline abstract_t\">Miranda MA, Ferraz &Aacute;A, Domingues AL, et al. Improvement of schistosomal portal hypertensive colopathy after surgical treatment. Arq Gastroenterol 2013; 50:153.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/31\" class=\"nounderline abstract_t\">Ferrari TC, Moreira PR, Cunha AS. Clinical characterization of neuroschistosomiasis due to Schistosoma mansoni and its treatment. Acta Trop 2008; 108:89.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/32\" class=\"nounderline abstract_t\">Peregrino AJ, Puglia PM, Nobrega JP, et al. [Schistosomiasis of the spinal cord: analysis of 80 cases]. Arq Neuropsiquiatr 2002; 60:603.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/33\" class=\"nounderline abstract_t\">Fowler R, Lee C, Keystone JS. The role of corticosteroids in the treatment of cerebral schistosomiasis caused by Schistosoma mansoni: case report and discussion. Am J Trop Med Hyg 1999; 61:47.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/34\" class=\"nounderline abstract_t\">Silva LC, Maciel PE, Ribas JG, et al. Treatment of schistosomal myeloradiculopathy with praziquantel and corticosteroids and evaluation by magnetic resonance imaging: a longitudinal study. Clin Infect Dis 2004; 39:1618.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/35\" class=\"nounderline abstract_t\">Ferrari TC, Moreira PR. Neuroschistosomiasis: clinical symptoms and pathogenesis. Lancet Neurol 2011; 10:853.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/36\" class=\"nounderline abstract_t\">Jaur&eacute;guiberry S, Ansart S, Perez L, et al. Acute neuroschistosomiasis: two cases associated with cerebral vasculitis. Am J Trop Med Hyg 2007; 76:964.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/37\" class=\"nounderline abstract_t\">Ross AG, McManus DP, Farrar J, et al. Neuroschistosomiasis. J Neurol 2012; 259:22.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/38\" class=\"nounderline abstract_t\">Watt G, Adapon B, Long GW, et al. Praziquantel in treatment of cerebral schistosomiasis. Lancet 1986; 2:529.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/39\" class=\"nounderline abstract_t\">Brindley PJ, Sher A. Immunological involvement in the efficacy of praziquantel. Exp Parasitol 1990; 71:245.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/40\" class=\"nounderline abstract_t\">van Lieshout L, Stelma FF, Guiss&eacute; F, et al. The contribution of host-related factors to low cure rates of praziquantel for the treatment of Schistosoma mansoni in Senegal. Am J Trop Med Hyg 1999; 61:760.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/41\" class=\"nounderline abstract_t\">Stelma FF, Talla I, Sow S, et al. Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am J Trop Med Hyg 1995; 53:167.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/42\" class=\"nounderline abstract_t\">Neumayr AL, Tschirky B, Warren A, et al. Acute febrile respiratory reaction after praziquantel treatment during asymptomatic late form of acute schistosomiasis. J Travel Med 2012; 19:264.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/43\" class=\"nounderline abstract_t\">Savioli L, Crompton DW, Neira M. Use of anthelminthic drugs during pregnancy. Am J Obstet Gynecol 2003; 188:5.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/44\" class=\"nounderline abstract_t\">Adam I, Elwasila el T, Homeida M. Is praziquantel therapy safe during pregnancy? Trans R Soc Trop Med Hyg 2004; 98:540.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/45\" class=\"nounderline abstract_t\">Adam I, Elwasila E, Homeida M. Praziquantel for the treatment of schistosomiasis mansoni during pregnancy. Ann Trop Med Parasitol 2005; 99:37.</a></li><li class=\"breakAll\">World Health Organization. Report of the WHO informal consultation on the use of praziquantel during pregnancy/lactation and albendazole/mebendazole in children under 24 months. World Health Organization, Geneva 2002.</li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/47\" class=\"nounderline abstract_t\">Olveda RM, Acosta LP, Tallo V, et al. Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2016; 16:199.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/48\" class=\"nounderline abstract_t\">Cioli D. Chemotherapy of schistosomiasis: an update. Parasitol Today 1998; 14:418.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/49\" class=\"nounderline abstract_t\">Gryseels B, Stelma F, Talla I, et al. Immuno-epidemiology of Schistosoma mansoni infections in a recently exposed community in Senegal. Mem Inst Oswaldo Cruz 1995; 90:271.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/50\" class=\"nounderline abstract_t\">Gryseels B, Mbaye A, De Vlas SJ, et al. Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop Med Int Health 2001; 6:864.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/51\" class=\"nounderline abstract_t\">Alonso D, Mu&ntilde;oz J, Gasc&oacute;n J, et al. Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection. Am J Trop Med Hyg 2006; 74:342.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/52\" class=\"nounderline abstract_t\">Silva IM, Thiengo R, Concei&ccedil;&atilde;o MJ, et al. Therapeutic failure of praziquantel in the treatment of Schistosoma haematobium infection in Brazilians returning from Africa. Mem Inst Oswaldo Cruz 2005; 100:445.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/53\" class=\"nounderline abstract_t\">Ismail M, Botros S, Metwally A, et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 1999; 60:932.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/54\" class=\"nounderline abstract_t\">Herwaldt BL, Tao LF, van Pelt W, et al. Persistence of Schistosoma haematobium infection despite multiple courses of therapy with praziquantel. Clin Infect Dis 1995; 20:309.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/55\" class=\"nounderline abstract_t\">Helleberg M, Thybo S. High rate of failure in treatment of imported schistosomiasis. J Travel Med 2010; 17:94.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/56\" class=\"nounderline abstract_t\">Sayed AA, Simeonov A, Thomas CJ, et al. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med 2008; 14:407.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/57\" class=\"nounderline abstract_t\">Cioli D, Pica-Mattoccia L, Basso A, Guidi A. Schistosomiasis control: praziquantel forever? Mol Biochem Parasitol 2014; 195:23.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/58\" class=\"nounderline abstract_t\">Ara&uacute;jo N, Kohn A, Katz N. Activity of the artemether in experimental schistosomiasis mansoni. Mem Inst Oswaldo Cruz 1991; 86 Suppl 2:185.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/59\" class=\"nounderline abstract_t\">Keiser J, Silu&eacute; KD, Adiossan LK, et al. Praziquantel, mefloquine-praziquantel, and mefloquine-artesunate-praziquantel against Schistosoma haematobium: a randomized, exploratory, open-label trial. PLoS Negl Trop Dis 2014; 8:e2975.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/60\" class=\"nounderline abstract_t\">Elmorshedy H, Tanner M, Bergquist RN, et al. Prophylactic effect of artemether on human schistosomiasis mansoni among Egyptian children: A randomized controlled trial. Acta Trop 2016; 158:52.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/61\" class=\"nounderline abstract_t\">Tanaka H, Tsuji M. From discovery to eradication of schistosomiasis in Japan: 1847-1996. Int J Parasitol 1997; 27:1465.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/62\" class=\"nounderline abstract_t\">Wang LD, Chen HG, Guo JG, et al. A strategy to control transmission of Schistosoma japonicum in China. N Engl J Med 2009; 360:121.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/63\" class=\"nounderline abstract_t\">Steinmann P, Keiser J, Bos R, et al. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006; 6:411.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/64\" class=\"nounderline abstract_t\">Jackson F, Doherty JF, Behrens RH. Schistosomiasis prophylaxis in vivo using N,N-diethyl-m-toluamide (DEET). Trans R Soc Trop Med Hyg 2003; 97:449.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/65\" class=\"nounderline abstract_t\">Fenwick A. Waterborne infectious diseases--could they be consigned to history? Science 2006; 313:1077.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/66\" class=\"nounderline abstract_t\">Mutapi F, Maizels R, Fenwick A, Woolhouse M. Human schistosomiasis in the post mass drug administration era. Lancet Infect Dis 2017; 17:e42.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/67\" class=\"nounderline abstract_t\">Harn DA, Reynolds SR, Chikunguwo S, et al. Synthetic peptide vaccines for schistosomiasis. Pharm Biotechnol 1995; 6:891.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/68\" class=\"nounderline abstract_t\">Lebens M, Sun JB, Czerkinsky C, Holmgren J. Current status and future prospects for a vaccine against schistosomiasis. Expert Rev Vaccines 2004; 3:315.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/69\" class=\"nounderline abstract_t\">Ribeiro de Jesus A, Ara&uacute;jo I, Bacellar O, et al. Human immune responses to Schistosoma mansoni vaccine candidate antigens. Infect Immun 2000; 68:2797.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/70\" class=\"nounderline abstract_t\">Richter D, Reynolds SR, Harn DA. Candidate vaccine antigens that stimulate the cellular immune response of mice vaccinated with irradiated cercariae of Schistosoma mansoni. J Immunol 1993; 151:256.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/71\" class=\"nounderline abstract_t\">Tran MH, Pearson MS, Bethony JM, et al. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nat Med 2006; 12:835.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-schistosomiasis/abstract/72\" class=\"nounderline abstract_t\">Merrifield M, Hotez PJ, Beaumier CM, et al. Advancing a vaccine to prevent human schistosomiasis. Vaccine 2016; 34:2988.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5705 Version 17.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H13464920\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H13464824\" id=\"outline-link-H13464824\">INTRODUCTION</a></li><li><a href=\"#H13464830\" id=\"outline-link-H13464830\">TREATMENT</a><ul><li><a href=\"#H7370613\" id=\"outline-link-H7370613\">Clinical approach</a><ul><li><a href=\"#H5762846\" id=\"outline-link-H5762846\">- Acute infection</a><ul><li><a href=\"#H5763226\" id=\"outline-link-H5763226\">Swimmer's itch</a></li><li><a href=\"#H5762942\" id=\"outline-link-H5762942\">Acute schistosomiasis syndrome</a></li></ul></li><li><a href=\"#H5762853\" id=\"outline-link-H5762853\">- Chronic infection</a><ul><li><a href=\"#H2484781\" id=\"outline-link-H2484781\">Overview</a></li><li><a href=\"#H5763365\" id=\"outline-link-H5763365\">Genitourinary schistosomiasis</a></li><li><a href=\"#H332980396\" id=\"outline-link-H332980396\">Hepatosplenic schistosomiasis</a></li><li><a href=\"#H2484977\" id=\"outline-link-H2484977\">Neuroschistosomiasis</a></li></ul></li></ul></li><li><a href=\"#H2484726\" id=\"outline-link-H2484726\">Anthelminthic therapy</a><ul><li><a href=\"#H13464848\" id=\"outline-link-H13464848\">- Praziquantel</a></li><li><a href=\"#H7366350\" id=\"outline-link-H7366350\">- Drug resistance</a></li><li><a href=\"#H7366108\" id=\"outline-link-H7366108\">- Alternative therapies</a></li></ul></li></ul></li><li><a href=\"#H13464908\" id=\"outline-link-H13464908\">PREVENTION</a></li><li><a href=\"#H13464920\" id=\"outline-link-H13464920\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H13464927\" id=\"outline-link-H13464927\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/5705|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/50021\" class=\"graphic graphic_table\">- Drug ratings in pregnancy (US Food and Drug Administration)</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-schistosomiasis\" class=\"medical medical_review\">Diagnosis of schistosomiasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-pathogenesis-and-clinical-manifestations-of-schistosomiasis\" class=\"medical medical_review\">Epidemiology, pathogenesis, and clinical manifestations of schistosomiasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mass-drug-administration-for-control-of-parasitic-infections\" class=\"medical medical_review\">Mass drug administration for control of parasitic infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-management-of-epilepsy-in-adults\" class=\"medical medical_review\">Overview of the management of epilepsy in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pruritus-overview-of-management\" class=\"medical medical_review\">Pruritus: Overview of management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=schistosomiasis-and-glomerular-disease\" class=\"medical medical_review\">Schistosomiasis and glomerular disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=strongyloidiasis\" class=\"medical medical_review\">Strongyloidiasis</a></li></ul></div></div>","javascript":null}